CAMBRIDGE, Mass., March 31, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present at the 2014 AACR Annual Meeting. The conference will take place on April 5-9, 2014 at the San Diego Convention Center in San Diego. Presentations will include a clinical pilot study evaluating the feasibility of using ferumoxytol * as an MRI imaging agent prior to MM-398 investigational treatment. Additional preclinical presentations describe the relationship between ferumoxytol and MM-398 tumor uptake and activity, as well as exploring the mechanistic basis of MM-398 activity across multiple tumor models. Data will be presented in four poster sessions. Poster Sessions
- Session Title: Clinical Trials Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as tumor imaging agent prior to MM-398, a nanoliposomal irinotecan (nal-IRI) Monday, April 7, 2014 8:00 AM - 12:00 PM Hall A-E, Poster Section 38
- Session Title: Tumor Biology 24 Magnetic resonance imaging with an iron oxide nanoparticle demonstrates the preclinical feasibility of predicting intratumoral uptake and activity of MM-398, a nanoliposomal irinotecan (nal-IRI) Monday, April 7, 2014 1:00 PM - 5:00 PM Hall A-E, Poster Section 7
- Session Title: Tumor Biology 38 Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewings family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression Tuesday, April 8, 2014 1:00 PM - 5:00 PM Hall A-E, Poster Section 5
- Session Title: Experimental and Molecular Therapeutics 37 Evaluating the pharmacodynamics and pharmacokinetic effects of MM-398, a nanoliposomal irinotecan (nal-IRI), in subcutaneous xenograft tumor models of human squamous cell carcinoma and small cell lung cancers Tuesday, April 8, 2014 1:00 PM - 5:00 PM Hall A-E, Poster Section 35
About Merrimack
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six oncology therapeutics in clinical development. For more information, please visit Merrimack's website at www.merrimackpharma.com. Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so. *Ferumoxytol (FMX), also known as Feraheme® (AMAG Pharmaceuticals), is a 30nm iron-oxide, super-paramagnetic nanoparticle, known to be taken up by macrophages and for exhibiting magnetic resonance imaging properties. The U.S. Food and Drug Administration has approved FMX for intravenous use as an iron replacement product for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). The use of FMX in the pilot study mentioned above is for clinical investigational studies only.CONTACT: Media Contacts: Debbie Tseng, Merrimack 617-441-7659 dtseng@merrimackpharma.com Heather Gitlitz, Spectrum 202-955-6222 hgitlitz@spectrumscience.com
